CINECA IRIS Institutional Research Information System

MORETTO, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.328
AS - Asia 1.254
EU - Europa 787
SA - Sud America 243
AF - Africa 71
OC - Oceania 2
Totale 4.685
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.267
SG - Singapore 430
CN - Cina 307
IT - Italia 238
HK - Hong Kong 207
BR - Brasile 191
VN - Vietnam 145
SE - Svezia 98
DE - Germania 94
GB - Regno Unito 94
BG - Bulgaria 64
FR - Francia 63
CA - Canada 38
IN - India 37
FI - Finlandia 31
RU - Federazione Russa 30
JP - Giappone 28
CI - Costa d'Avorio 26
AR - Argentina 23
BD - Bangladesh 19
TR - Turchia 19
PL - Polonia 16
KR - Corea 14
ZA - Sudafrica 14
AT - Austria 10
ES - Italia 10
NG - Nigeria 10
SN - Senegal 10
ID - Indonesia 9
MX - Messico 9
IQ - Iraq 8
NL - Olanda 8
UA - Ucraina 7
EC - Ecuador 6
SA - Arabia Saudita 6
CO - Colombia 5
CZ - Repubblica Ceca 5
IE - Irlanda 5
PK - Pakistan 5
CL - Cile 4
HN - Honduras 4
MA - Marocco 4
VE - Venezuela 4
CH - Svizzera 3
NP - Nepal 3
PE - Perù 3
PS - Palestinian Territory 3
PY - Paraguay 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BO - Bolivia 2
DZ - Algeria 2
LT - Lituania 2
PA - Panama 2
PT - Portogallo 2
RO - Romania 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BW - Botswana 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
KY - Cayman, isole 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 4.685
Salva come PNG Salva come JPEG
Città #
Ashburn 258
Singapore 236
Hong Kong 202
Dallas 194
Fairfield 177
Santa Clara 174
San Jose 164
Woodbridge 153
Chandler 111
Shanghai 97
Seattle 85
Houston 82
Cambridge 75
Wilmington 70
Sofia 63
New York 60
Ann Arbor 58
Los Angeles 53
Beijing 48
Boardman 45
London 43
Munich 38
Florence 37
Ho Chi Minh City 33
Princeton 30
Lawrence 28
Milan 28
Pisa 28
Abidjan 26
Tokyo 25
Lauterbourg 22
Hanoi 21
Hefei 21
Ottawa 21
Serra 19
Frankfurt am Main 18
Medford 18
São Paulo 18
Council Bluffs 17
Redondo Beach 17
Cascina 16
Bremen 15
Dearborn 15
Warsaw 15
Des Moines 14
Istanbul 14
Ogden 14
Seoul 14
Turku 14
Lancaster 13
Buffalo 12
Rio de Janeiro 11
Dakar 10
Düsseldorf 10
Helsinki 10
Lagos 10
Seacroft 10
Orem 9
Vienna 9
Da Nang 8
Dong Ket 7
Fuzhou 7
Montreal 7
Nanjing 7
San Diego 7
Brooklyn 6
Curitiba 6
Fortaleza 6
Johannesburg 6
Redwood City 6
Toronto 6
Chennai 5
Denver 5
Dublin 5
Guarulhos 5
Haiphong 5
Phoenix 5
Poplar 5
Turin 5
Verona 5
Atlanta 4
Baghdad 4
Genoa 4
Mumbai 4
Paris 4
Rome 4
Shenyang 4
Asunción 3
Belo Horizonte 3
Boston 3
Brasília 3
Bromsgrove 3
Chicago 3
Coreglia Antelminelli 3
Hebei 3
Lima 3
Nanchang 3
Norwalk 3
Nuremberg 3
Qingdao 3
Totale 3.339
Salva come PNG Salva come JPEG
Nome #
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 178
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 175
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 170
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 166
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 165
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 162
The landscape of alterations in DNA damage response pathways in colorectal cancer 162
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 160
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 159
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 159
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 158
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 157
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 156
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 152
A still missing piece of the FIRE-3 puzzle 148
Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer 146
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 143
BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases 139
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 132
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 131
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 128
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 123
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 123
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 122
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients 121
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation 116
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study 112
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 112
Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection 107
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 105
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 99
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 99
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 98
null 85
null 65
Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment 20
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 15
Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal cancer. A narrative review and evidence-based algorithm 13
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 13
Totale 4.794
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.111
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.111
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202149 0 0 0 0 0 0 0 0 0 0 0 49
2021/2022241 3 2 6 1 46 53 2 9 13 22 15 69
2022/2023417 42 68 38 29 41 44 7 30 60 0 55 3
2023/2024337 23 25 49 21 48 47 26 10 10 10 33 35
2024/20251.188 12 35 30 58 107 146 118 52 110 138 115 267
2025/20261.580 96 190 231 205 147 99 196 73 92 146 90 15
Totale 4.794